Canine Parvovirus: Symptoms, Diagnosis, Treatment & Prevention

Quick Q&A

Question: What are the first signs of parvo in a puppy? Answer: The earliest signs of parvo are lethargy, loss of appetite, and fever, often followed within 24-48 hours by projectile vomiting and severe, foul-smelling bloody diarrhea. If your puppy shows any of these signs, seek emergency veterinary care immediately, as the disease progresses rapidly.

Question: Can a vaccinated dog get parvovirus? Answer: Yes, breakthrough infections can occur, especially with emerging variants like CPV-2c [36]. Vaccination significantly reduces the severity of disease, but no vaccine provides 100% sterilizing immunity. Puppies are most vulnerable until they complete their full series of boosters.

Question: How is parvo treated in dogs? Answer: Treatment is primarily supportive and includes aggressive intravenous fluid therapy, antiemetics (maropitant, ondansetron), antibiotics to prevent secondary sepsis, nutritional support, and strict isolation. Hospitalization for 3-7 days is typical, with survival rates above 90% with intensive care.

Question: How long does parvo live on surfaces? Answer: Canine parvovirus is extremely stable in the environment and can survive on surfaces, clothing, and soil for months to years if not properly disinfected. It is resistant to many common household cleaners but is inactivated by bleach (sodium hypochlorite) and potassium peroxymonosulfate.

Introduction

Canine parvovirus (CPV-2) remains one of the most significant infectious disease threats to dogs worldwide. Despite widespread vaccination, this highly contagious and often fatal virus continues to cause outbreaks, particularly in shelters, breeding kennels, and areas with low vaccination coverage. The emergence of new antigenic variants (CPV-2a, CPV-2b, and CPV-2c) has complicated the epidemiological landscape, with reports of breakthrough infections in vaccinated animals becoming increasingly common [36][7].

This exhaustive master reference guide is designed for veterinary professionals, veterinary students, and dedicated pet owners. It provides a deep, evidence-based exploration of the etiology, transmission, clinical signs, diagnostic approaches, treatment protocols, and prevention strategies for canine parvovirus. We integrate the latest 2026 research findings, including studies on monoclonal antibody therapy, fecal microbiota transplantation, novel diagnostic tools, and the molecular epidemiology of emerging variants.

Etiology and Virology

Canine parvovirus is a small, non-enveloped, single-stranded DNA virus belonging to the genus Protoparvovirus within the family Parvoviridae. Its lack of a lipid envelope makes it exceptionally resistant to environmental inactivation and many common disinfectants.

Antigenic Variants: CPV-2, CPV-2a, CPV-2b, and CPV-2c

The original CPV-2 emerged in the late 1970s and rapidly spread globally. Within a few years, it evolved into two antigenic variants, CPV-2a and CPV-2b, which largely replaced the original strain. More recently, CPV-2c has emerged and is now the predominant variant in many regions.

• CPV-2a and CPV-2b: These variants differ from the original CPV-2 by a few key amino acid substitutions in the VP2 capsid protein. They are considered the "classic" field strains and are well-covered by modern vaccines.
• CPV-2c: This variant, first identified in Italy, is characterized by a specific mutation (Glu-426) that alters its antigenic profile. Studies have shown that CPV-2c can cause disease in vaccinated dogs, raising concerns about vaccine efficacy [36][7]. A 2026 study from central Spain found that CPV-2c was associated with higher in-hospital mortality compared to other variants [7]. The "Asian" CPV-2c variant has also been reported in Europe, as documented in a 2026 case report from Slovakia involving a vaccinated dog [3].
• Global Distribution: The prevalence of specific variants varies geographically. CPV-2c is now common in Europe, South America, and parts of Asia and Africa [10][28]. A 2026 survey in Guinea confirmed the presence of CPV-2 in West Africa [5], while genomic surveillance in Ghana identified CPV-2 at human-animal interfaces [11].

Viral Stability in the Environment

The environmental persistence of CPV is a major challenge for infection control. The virus can survive for months indoors at room temperature and for years in cool, dark, and moist environments like soil. It is resistant to many common household disinfectants, including quaternary ammonium compounds and alcohol.

• Soil and Surfaces: CPV can remain infectious in contaminated soil for over a year. This is a particular concern for dog parks, kennels, and homes with a history of parvo.
• Fomites: The virus is readily transmitted via fomites, including shoes, clothing, food bowls, leashes, and bedding.
• Disinfection: Effective disinfection requires the use of specific agents. Sodium hypochlorite (household bleach) at a 1:32 dilution (1/2 cup of bleach per gallon of water) with a 10-minute contact time is highly effective. Potassium peroxymonosulfate (e.g., Virkon S or Trifectant) is another reliable disinfectant used in veterinary settings.

Transmission and Epidemiology

Transmission Routes

Transmission occurs primarily through the fecal-oral route. A susceptible dog becomes infected by ingesting the virus from a contaminated environment.

• Direct Contact: Direct contact with an infected dog's feces, vomit, or saliva.
• Indirect Contact (Fomites): This is the most common route. Owners, veterinary staff, and other animals can carry the virus on their hands, shoes, or clothing from one location to another.
• Vectors: Insects and rodents can serve as mechanical vectors.

Incubation Period and Shedding

The incubation period is typically 3 to 7 days. Viral shedding in feces begins before clinical signs appear (as early as day 3 post-infection) and can continue for up to 2-3 weeks after recovery. This means a seemingly healthy puppy can be contagious.

Risk Factors

• Age: Puppies between 6 weeks and 6 months of age are most susceptible. Maternal antibody interference can prevent effective vaccination in very young puppies.
• Breed: Certain breeds, including Rottweilers, Doberman Pinschers, German Shepherds, and Pit Bull-type dogs, appear to be at higher risk for severe disease.
• Vaccination Status: Incomplete or absent vaccination is the single biggest risk factor. Breakthrough infections, while possible, are typically less severe.
• Stress and Co-infections: Stress from weaning, transport, or overcrowding can immunosuppress an animal. Co-infections with canine circovirus (CanineCV) or canine coronavirus are common and can worsen clinical outcomes [6][18]. A 2026 study from Vietnam highlighted the prevalence of CPV-circovirus co-infections in diarrheic dogs [6].

Clinical Signs and Symptoms

The clinical presentation of canine parvovirus can range from mild, subclinical infection to rapid, fatal disease. The classic presentation is severe hemorrhagic gastroenteritis, but the virus can also cause myocarditis in very young puppies.

Early Warning Signs (Prodromal Phase)

The earliest signs of parvo are often non-specific and can be mistaken for other conditions. Recognizing these signs of parvo is critical for early intervention.

• Lethargy: The dog becomes unusually tired, depressed, and uninterested in play or interaction.
• Anorexia: A complete loss of appetite is common.
• Fever: A fever of 103-106°F (39.5-41°C) is often present in the early stages. Some dogs may become hypothermic later as they go into shock.
• Vomiting: This often starts as clear or yellow bile and progresses to projectile vomiting.

Advanced Signs (Gastroenteritis Phase)

Within 24-48 hours, the hallmark signs of parvo appear.

• Severe, Bloody Diarrhea: The diarrhea is profuse, watery, and often contains frank blood. It has a characteristically fetid, sweet-sour odor that many experienced veterinarians can recognize immediately.
• Persistent Projectile Vomiting: The dog vomits repeatedly, often unable to keep down even water.
• Dehydration and Shock: Due to massive fluid and protein loss through vomiting and diarrhea, the dog rapidly becomes dehydrated. Signs include sunken eyes, dry gums, and a loss of skin elasticity. Hypovolemic shock can develop quickly.
• Abdominal Pain: The dog may exhibit a "praying position" (sternal recumbency with the hindquarters raised) due to abdominal pain.
• Sepsis: The damaged intestinal barrier allows bacteria from the gut to enter the bloodstream, leading to septicemia and systemic inflammatory response syndrome (SIRS).

Atypical Presentations

• Myocarditis: This form is seen in very young (neonatal) puppies infected in utero or shortly after birth. The virus attacks the heart muscle, leading to acute heart failure and sudden death. A 2026 case report documented fatal myocarditis in a litter of one-day-old German Shepherd puppies [17].
• Peripheral Polyneuropathy: A rare but documented neurological complication. A 2026 study described three puppies that developed acute polyradiculoneuritis (a Guillain-Barre-like syndrome) temporally associated with CPV infection [4].
• Ocular Manifestations: A 2026 study found that juvenile dogs with CPV can have measurable changes in tear production and intraocular pressure, though these are not primary clinical signs [8].

Diagnosis

Rapid and accurate diagnosis is essential for initiating appropriate treatment and implementing isolation protocols.

In-Clinic Diagnostic Tests

• ELISA Snap Test: The most common point-of-care test. It detects CPV antigen in a fecal sample. The test is highly specific (few false positives) but has variable sensitivity, especially in the early stages of infection or after vaccination with a modified-live vaccine (which can cause a transient false positive). A 2026 study evaluating a dot-blot ELISA showed strong agreement with the gold-standard hemagglutination inhibition test for antibody detection [32].
• Fecal Hemagglutination: A less common test that relies on the virus's ability to agglutinate red blood cells.
• Quantitative PCR (qPCR): This is the gold standard for diagnosis. It is highly sensitive and specific and can detect the virus even in low amounts. It can also be used to quantify viral load and differentiate between vaccine and field strains. A 2026 study developed two qPCR assays with high-resolution melting analysis for differentiating CPV from feline panleukopenia virus [40].

Laboratory Diagnostics

• Complete Blood Count (CBC): A classic finding is panleukopenia (a severe drop in white blood cell count), particularly lymphopenia and neutropenia. A 2026 study investigated the neutrophil myeloperoxidase index as a potential biomarker in juvenile dogs with parvoviral enteritis [33].
• Serum Biochemistry: May reveal electrolyte imbalances, hypoglycemia, hypoalbuminemia, and elevated liver enzymes.
• Virus Isolation and Sequencing: Used for research and epidemiological surveillance. Molecular characterization of circulating strains is crucial for tracking variant evolution [28][10].

Differential Diagnoses

Several other conditions can mimic the signs of parvo. A thorough diagnostic workup is necessary to rule out:

• Hemorrhagic Gastroenteritis (HGE): Often of unknown cause but can present identically. The key difference is that HGE typically does not cause leukopenia.
• Canine Distemper: Can cause gastrointestinal signs but is more commonly associated with respiratory and neurological signs.
• Intestinal Parasites: Heavy burdens of hookworms or roundworms can cause bloody diarrhea in puppies.
• Dietary Indiscretion: Ingestion of toxins or foreign bodies can cause acute gastroenteritis.
• Other Viral Infections: Canine coronavirus, rotavirus, and circovirus can cause similar signs, often as co-infections [6][23].

Treatment and Management

There is no specific antiviral drug approved for CPV. Treatment is entirely supportive, focusing on maintaining hydration, controlling vomiting, preventing secondary infections, and providing nutritional support. The level of care can vary widely based on financial constraints and hospital capabilities.

Outpatient vs. ICU Hospitalization Protocols

• ICU Hospitalization: This is the gold standard and offers the best chance of survival (90-95%). It involves continuous IV fluid therapy, constant monitoring, and 24/7 nursing care.
• Outpatient (Subcutaneous) Therapy: For mild cases or when owners cannot afford hospitalization, a subcutaneous fluid protocol may be attempted. This has a lower success rate (60-70%) but can be a viable option. A 2026 randomized controlled trial evaluated oral fecal microbial transplant (FMT) as a low-cost outpatient intervention [20].

IV Fluid Resuscitation

Fluid therapy is the cornerstone of treatment.

• Crystalloids: Balanced isotonic crystalloids (e.g., Lactated Ringer's Solution, Normosol-R) are the primary fluids. The goal is to correct dehydration, replace ongoing losses, and maintain perfusion.
• Colloids: In cases of severe hypoalbuminemia (low protein), synthetic colloids (e.g., hetastarch) or natural colloids (plasma transfusions) may be used to help maintain oncotic pressure.
• Additives: Dextrose is added to correct hypoglycemia. Potassium chloride is added to correct hypokalemia. B vitamins can be added to the fluids.

Antiemetic Therapy

Controlling vomiting is critical to allow for fluid absorption and eventual enteral nutrition.

• Maropitant (Cerenia): A neurokinin-1 receptor antagonist. It is the most effective antiemetic for CPV and also has some visceral analgesic properties.
• Ondansetron (Zofran): A 5-HT3 receptor antagonist. It is often used in combination with maropitant for refractory vomiting.
• Metoclopramide: A prokinetic agent that can be used, but it is less effective than maropitant or ondansetron.

Antibiotic Therapy

The damaged intestinal mucosa allows bacterial translocation, leading to sepsis. Broad-spectrum antibiotics are indicated.

• Ampicillin/Sulbactam or Amoxicillin/Clavulanate: For gram-positive and anaerobic coverage.
• Enrofloxacin or Marbofloxacin: For gram-negative coverage. Fluoroquinolones should be used with caution in young, growing dogs due to the risk of arthropathy.

Nutritional Support

Historically, dogs were kept NPO (nothing by mouth) to rest the gut. Current evidence strongly supports early enteral nutrition.

• Nasoesophageal (NE) Tube: A soft tube placed through the nose into the esophagus allows for continuous or bolus feeding of a liquid diet.
• Feeding Protocol: Small, frequent meals of a highly digestible, low-residue diet (e.g., Hill's i/d, Royal Canin Gastrointestinal) are started as soon as vomiting is controlled. Early enteral nutrition helps maintain gut barrier integrity, reduces bacterial translocation, and speeds recovery.

Adjunctive Therapies

• Monoclonal Antibody Therapy: A 2026 retrospective study found that a CPV monoclonal antibody product supported faster clinical recovery in shelter dogs with naturally occurring CPV [1]. This represents a promising new avenue for treatment.
• Fecal Microbiota Transplantation (FMT): FMT aims to restore a healthy gut microbiome. A 2026 study found that a specific FMT dosing regimen accelerated clinical resolution in CPV infection [34]. Another 2026 trial explored its use in an outpatient setting [20].
• Saccharomyces boulardii: This probiotic yeast has shown anti-inflammatory effects in dogs naturally infected with CPV, potentially modulating the immune response [27].
• Oseltamivir (Tamiflu): An antiviral drug that has been used experimentally for CPV, but its efficacy is not well-established and it is not considered standard of care.
• Plasma Transfusion: Provides passive immunity (antibodies) and albumin. It is most beneficial in the early stages of the disease.

Prognosis and Survival

With intensive care, survival rates exceed 90%. Without treatment, mortality approaches 90%. Factors associated with a worse prognosis include:

• Young age (< 8 weeks)
• Severe leukopenia
• Hypoglycemia
• Hypoalbuminemia
• Co-infections [6]
• Infection with CPV-2c variant [7]
• Delay in seeking treatment

A 2026 study from Ghana identified specific clinical factors and service types associated with outcomes [15]. Another study from the same institution analyzed survival patterns and prognostic factors [2].

Prevention

Prevention is far more effective and cost-efficient than treatment.

Vaccination

Vaccination is the single most important preventive measure.

• Core Vaccine: The CPV vaccine is considered a core vaccine by the AVMA, AAHA, WSAVA, and all major veterinary organizations.
• Puppy Series: Puppies should receive a series of vaccines starting at 6-8 weeks of age, repeated every 2-4 weeks until 16-20 weeks of age. The final dose should be given at or after 16 weeks to overcome maternal antibody interference.
• Adult Boosters: After the initial puppy series, a booster is given at 1 year of age, and then every 3 years thereafter (as per AAHA guidelines).
• Vaccine Types:
  • Modified-Live Virus (MLV): Provides the most robust and rapid immunity. It is the standard for puppies and most adult dogs.
  • Inactivated (Killed) Virus: Safer for use in pregnant dogs or immunocompromised animals, but provides a less robust immune response.
• Breakthrough Infections: Despite vaccination, breakthrough infections can occur, particularly with CPV-2c. A 2026 study from Nigeria investigated factors associated with breakthrough infection [22]. A study from Egypt highlighted the role of vaccination practices and viral antigenic variation [36].

Disinfection Protocols

Given the virus's environmental stability, rigorous disinfection is required.

• For Homes and Kennels:
  1. Clean all organic matter (feces, vomit, dirt) thoroughly with detergent and water.
  2. Apply a 1:32 dilution of household bleach (sodium hypochlorite) with a 10-minute contact time. Caution: Bleach is corrosive and can damage surfaces and fabrics. Rinse thoroughly.
  3. Potassium peroxymonosulfate (e.g., Virkon S, Trifectant) is an excellent alternative that is less corrosive. Follow label instructions for dilution and contact time.
  4. Steam cleaning can also help inactivate the virus on carpets and upholstery.
• For Veterinary Hospitals:
  • Strict isolation protocols for suspected cases.
  • Use of dedicated equipment (stethoscopes, thermometers).
  • Hand hygiene with chlorhexidine-based scrubs.
  • Disinfection of all surfaces with potassium peroxymonosulfate or bleach.

Biosecurity for Shelters and Kennels

• Quarantine: Any new dog should be quarantined for a minimum of 7-10 days before being introduced to the general population.
• Cohorting: Separate dogs by age and risk status (e.g., unvaccinated puppies, adults).
• Traffic Flow: Implement a "clean to dirty" flow, where staff move from healthy to sick areas last.

Managing a Parvo-Positive Household

If your dog is diagnosed with parvo, you must take steps to protect other dogs and prevent re-infection.

1. Isolate the Sick Dog: Keep the infected dog in a separate, easily disinfected area (e.g., a bathroom or laundry room).
2. Use Dedicated Items: Use separate food and water bowls, bedding, and toys for the sick dog.
3. Practice Strict Hygiene: Wear gloves and a dedicated pair of shoes when caring for the sick dog. Wash your hands thoroughly with soap and water after any contact. Change your clothes before interacting with other dogs.
4. Disinfect the Environment: Clean and disinfect all surfaces the sick dog has contacted. Discard porous items (carpets, bedding) that cannot be effectively disinfected.
5. Wait to Adopt: Do not bring a new, unvaccinated puppy into the home for at least 6 months to a year after a parvo infection, as the virus can persist in the environment.

FAQs

Q: Can humans catch parvo from dogs? A: No. The canine parvovirus is species-specific and cannot infect humans. However, humans can act as fomites, carrying the virus on their hands and clothing to other dogs.

Q: What is the cost of parvo treatment? A: The cost can vary widely. Outpatient treatment may cost several hundred dollars, while intensive in-hospital care can range from $1,500 to $5,000 or more, depending on the duration of hospitalization and the complexity of the case.

Q: Is there a home test for parvo? A: Yes, there are over-the-counter ELISA test kits available for purchase. However, they are not as accurate as a veterinarian's in-clinic test, and a false negative can give a dangerous sense of security. A veterinary diagnosis is always recommended.

Q: How long does it take for a dog to recover from parvo? A: With treatment, most dogs show significant improvement within 3 to 7 days. Full recovery, including normalization of the stool and return of full energy, can take 2 to 4 weeks.

Q: What should I feed my dog after parvo? A: Feed a highly digestible, low-residue diet. Your veterinarian will recommend a specific prescription diet (e.g., Hill's i/d, Royal Canin Gastrointestinal, Purina EN). Feed small, frequent meals. Avoid high-fat or high-fiber foods.

Conclusion

Canine parvovirus remains a formidable pathogen, but it is a preventable and treatable disease. The key to reducing mortality lies in early recognition of the signs of parvo, rapid diagnostic testing, and aggressive supportive care. Advances in treatment, including monoclonal antibodies and FMT, are improving outcomes. However, the cornerstone of control remains widespread, consistent vaccination and rigorous environmental disinfection. By staying informed about emerging variants and adhering to best practices, veterinarians and pet owners can work together to protect the canine population from this devastating disease.

References

[1] Welton M, Hadden H, Herron M, et al. (2026). Retrospective evaluation of canine parvovirus monoclonal antibody supports faster clinical recovery in shelter dogs with naturally occurring canine parvovirus. J Am Vet Med Assoc. [2] Opoku ED, Folitse RD, Kodie DO, et al. (2026). Survival patterns and prognostic factors associated with canine parvovirus infection in dogs presented at the KNUST Veterinary Teaching Hospital in Kumasi, Ghana. BMC Vet Res. [3] Petroušková P, Pelegrinová A, Drážovská M, et al. (2026). Acute hemorrhagic gastroenteritis caused by an "Asian" CPV-2c variant in a vaccinated dog from Slovakia (Central Europe): a case report. Front Vet Sci. [4] Stan CM, Rusbridge C, Stabile F, et al. (2026). Peripheral polyneuropathy in three puppies temporally associated with canine parvovirus infection resembling acute polyradiculoneuritis. J Comp Pathol. [5] Kante N, Kaba L, Sanou M, et al. (2026). Epidemiological survey on canine parvovirus in the Urban Commune of Labé, Guinea. Companion Anim Health Genet. [6] Nguyen MT, Pham TLH, Nguyen HTT, et al. (2026). Clinicopathological profiling of diarrheic canine parvovirus-circovirus co-infections in Hanoi, Vietnam. Open Vet J. [7] Penelo S, Simarro I, Recuero MF, et al. (2026). Canine parvovirus type 2 antigenic variants and in-hospital mortality in central Spain: Retrospective and prospective data (2003-2014). Open Vet J. [8] Ozturan YA, Yaygingul R, Gultekin M, et al. (2026). Ocular Manifestations of Canine Parvovirus in Juvenile Dogs: Tear Production, Intraocular Pressure, Fundoscopic Findings, and Ultrasonographic Measurements. Vet Med Sci. [9] Mira F, Donato G, Schirò G, et al. (2026). Prevalence of Protoparvovirus carnivoran1/Feline Coronavirus and Associated Risk Factors in Cats Admitted to a Public Shelter in Southern Italy. Vet Sci. [10] Zobo AA, Kallo V, Diobo NF, et al. (2026). Canine Parvovirus Asian Type 2 Variant C (CPV-2c) Detected in Côte d'Ivoire. Viruses. [11] Paoli JE, Trovão NS, Odoom T, et al. (2026). One Health Genomic Surveillance at Human-Animal Interfaces in Rural Ghana Reveals Underreported Viruses of Zoonotic and Economic Concern. Viruses. [12] Araiza-Hernández DM, Vargas-Ruiz A, Marín-Flamand E, et al. (2026). Molecular Characterization of Helicase and Nuclease Domains in PPV5 NS1 from Mexican Full-Length Sequence. Viruses. [13] Feng X, Xu L, Zhang C, et al. (2026). Multilayered nucleotide organization reveals purifying selection and host-driven adaptation in CPV and FPV. BMC Vet Res. [14] Miao B, Du Q, Yang L, et al. (2026). Development of canine parvovirus-2-based recombinant pseudoviruses expression system: a potential vaccine platform. Vet Res. [15] Agbota JD, Folitse RD, Opoku ED, et al. (2026). Clinical factors, service type, and clinical outcomes associated with canine parvovirus in dogs presented at the KNUST Veterinary Teaching Hospital in Kumasi, Ghana. Companion Anim Health Genet. [16] Huang Z, Cheong U, Liu Z, et al. (2026). Surveillance of Parvovirus in Free-Roaming Dogs in the Qinling Mountains and Assessment of the Risk of Cross-Species Transmission to Giant Pandas. Animals (Basel). [17] Jarolmasjed S, Ghorani M, Shahbazfar AA, et al. (2026). Fatal Myocarditis Caused by Canine Parvovirus in a Litter of One-Day-Old German Shepherd Puppies: Molecular and Histopathological Findings. Vet Med Sci. [18] Minh H, Villanueva BHA, Chuang KP. (2026). Detection of canine circovirus (CanineCV) co-infection in canine parvovirus 2 (CPV-2) cases among domestic dogs in Vietnam, 2023-2024. Arch Virol. [19] Zersen K. (2026). Update on Canine Parvovirus. Vet Clin North Am Small Anim Pract. [20] Hoel ME, Gimenez AR, Elbe A, et al. (2026). Oral fecal microbial transplant for parvovirus in the outpatient setting: a randomized controlled trial to evaluate a practical and low-cost intervention. J Am Vet Med Assoc. [21] Gao B, Yi J, Gai L, et al. (2026). Development and Validation of a Recombinant VP2-Based Indirect ELISA for Canine Parvovirus. Microorganisms. [22] Shima FK, Gberindyer FA, Omobowale TO, et al. (2026). Clinic-based cross-sectional observational study of factors associated with canine parvovirus breakthrough infection among gastroenteritis cases in Nigeria. Prev Vet Med. [23] Campalto M, Mazzotta E, Crescenti F, et al. (2026). Molecular survey of mammalian orthoreovirus and Rotavirus A in Italian dogs and cats. Front Vet Sci. [24] Habte D, Wondimagegnehu K, Fhetanegest D. (2026). Parvoviral hemorrhagic gastroenteritis and its therapeutic intervention in a case of 5-month-old puppy. Companion Anim Health Genet. [25] Furtado MM, Soresini G, Jácomo ATA, et al. (2026). Pathogen Surveillance in Free-ranging Giant Otters (Pteronura brasiliensis) in Three Ecoregions of Brazil. J Wildl Dis. [26] Liu L, Xia M, Hou C, et al. (2026). Molecular Characterization of Representative CPV-2c Isolates and Establishment of VP2-Targeted Nanobody-Based Immunodetection Tools. Animals (Basel). [27] Laçin SSS, Hanedan B. (2026). Anti-inflammatory effects of Saccharomyces boulardii treatment in dogs naturally infected with canine parvovirus. Vet Immunol Immunopathol. [28] Xia Q, Liu J, Gui Y, et al. (2026). Molecular Characteristics and Genetic Diversity of Canine Parvovirus in Shanghai, China, from 2016 to 2025. Microorganisms. [29] Sharma S, Sharma P, Mandar RP, et al. (2026). Design of Multi-Epitope DIVA-Compatible Vaccine Candidate Against Canine Parvovirus 2. J Mol Recognit. [30] López-Astacio RA, Wasik BR, Lee H, et al. (2026). Distinct evolutionary patterns of endemic and emerging parvoviruses and the origin of a new pandemic virus. Proc Natl Acad Sci U S A. [31] Aslim HP, Gülbahçe R, Dik I, et al. (2026). Molecular characterisation of viral pathogens associated with respiratory and gastrointestinal infections in dogs in Türkiye - preliminary study. J Vet Res. [32] Talbot CT, Brewer M, Willis M, et al. (2026). Dot-blot ELISA assay demonstrates strong agreement with hemagglutination inhibition for the detection of canine parvovirus antibodies in sera of healthy, vaccinated blood-donor dogs. J Am Vet Med Assoc. [33] Loubser LC, Botha WJ, Rautenbach Y, et al. (2026). Neutrophil myeloperoxidase index in juvenile dogs with parvoviral enteritis. J Vet Diagn Invest. [34] Winston JA, Jennings R, Randolph NK, et al. (2026). Fecal microbiota transplantation dosing regimen accelerates clinical resolution in canine parvovirus infection: a novel spectrum-of-care approach. J Am Vet Med Assoc. [35] Yan Y, Ren X, Xiao Y, et al. (2026). The SIRT1-Mediated p53 Deacetylation Pathway Modulates Apoptosis and Promotes Viral Replication in MVC-Infected Cells. Pathogens. [36] Safwat MS, Khodeir MH, Etman RH. (2026). Canine parvovirus type 2 infection in vaccinated puppies: role of vaccination practices and viral antigenic variation. BMC Vet Res. [37] Liu G, Fu P, Zhang X, et al. (2026). Development of canine parvovirus-neutralizing monoclonal antibodies from natural host and their germline gene usage. Appl Microbiol Biotechnol. [38] Yan Z, Li B, Peng J, et al. (2026). Immunogenic evaluation of a recombinant rabies virus expressing canine distemper virus H gene and canine parvovirus VP2 gene. Vet J. [39] Behera SK, Maibam L, Lalhmangaihzuali M, et al. (2026). Genomic and immunoinformatic characterization of canine adenovirus type 1 in parvovirus-infected dogs: A comprehensive study from northeast India. Pol J Vet Sci. [40] Balboni A, Facile V, Urbani L, et al. (2026). Feline panleukopenia virus and canine parvovirus: development of two qPCR assays with high-resolution melting analysis and molecular epidemiology in dogs and cats from Northern Italy in 2017-2023. Front Vet Sci.